Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents - Modern Pathology
Breast cancer biomarkers, and a new clinical category for HER2 expression | Medical Laboratory Observer
Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer | Modern Pathology
HER2 Status Determined by 2007 and 2013 ASCO/CAP Criteria, Respectively... | Download Table
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.,JAMA Oncology - X-MOL
Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer
Summary of ASCO/CAP HER2 testing recommendations 2007 and 2013 | Download Table
What's New in the 2020 Update to the CAP/ASCO ER/PR Testing Guidelines in Breast Cancer?
Identification of challenges and a framework for implementation of the AMP/ ASCO/CAP classification guidelines for reporting somatic variants - ScienceDirect
The concordance between IHC and ISH for HER-2 testing in breast cancer in Nakhon Pathom Hospital, Thailand, based on the ASCO/CAP 2018 guidelines: a retrospecti
Brittany Harvey on X: "Listen to the latest @ASCO Guidelines podcast episode to hear co-chairs @awolff and @DrKimAllison discuss this ASCO-CAP HER2 testing guideline update with me, including the implications for clinicians
Pathologist's Corner – Dr. Hon on Breast Cancer Tissue Handling and Updates for Her-2 Testing
Updated (2018) ASCO/CAP Guidelines for HER2 Testing in Breast Cancer - Insights
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/ CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer | Virchows Archiv
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology
ASCO-CAP HER2 Test Guideline Recommendations PDF | PDF | Immunohistochemistry | Metastasis
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
ASCO 2020: HER2 Reclassification - Agendia Inc.
Le linee guida ASCO/CAP 2018
Q&A column - CAP TODAY
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update | Journal of Clinical Oncology
The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines | Journal of Clinical Pathology
![PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b66331181b2eafa14b6e478dcc7fced0c7917993/3-Table1-1.png "PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar")
PDF] HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation | Semantic Scholar
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Clinically actionable cancer somatic variants (CACSV): a tumor interpreted dataset for analytical workflows | BMC Medical Genomics | Full Text
HER2 IHC and Her2 FISH Criteria Under the 2007 and the 2013 ASCO/CAP... | Download Table
New ASCO-CAP Guidelines for HER2 Testing - Srl
